Most providers associate clinical documentation improvement (CDI) with the transition to ICD-10 coding, however, CDI - a process in which care providers receive feedback from specialists who review clinical documents - may also deliver clinical and financial benefits for healthcare organizations.
Most providers associate clinical documentation improvement (CDI) with the transition to ICD-10 coding, however, CDI — a process in which care providers receive feedback from specialists who review clinical documents — may also deliver clinical and financial benefits for healthcare organizations.
The main benefit of CDI is the feedback loop that it creates. It can fill the gaps in care including those found in documentation, coding, quality, and many other aspects involved with the overall care management of a patient.
Georges Feghali, MD, Chief Medical Officer and Chief Quality Officer at TriHealth Medical health system, said that his organization adopted CDI to develop consistency between the clinical and coding language that physicians use.
“The problem is that when physicians write in clinical terms that they understand, they assume everybody else understands those terms. But they don’t. For example, 1 term that is very commonly used is urosepsis. What urosepsis means to a physician is that somebody’s septic and the origin of the sepsis is urinary. But the coding interpretation of urosepsis is a urinary tract infection. With a urinary tract infection, you treat the patient with antibiotics for a couple of days and the problem is gone. No big deal. But actual urosepsis has a 25% mortality rate to it,” said Dr Feghali. “So in the physician and clinician’s mind, this translates to a very, very sick patient that’s in the ICU and has a 1 out of 4 chance of dying, and the coders are interpreting that as somebody who has a bladder infection, and walking around and should take 2 days of antibiotics. On 1 hand, you have somebody that looks like they should be in the outpatient setting. On the other hand, somebody’s going to die. If you end up measuring them in the same way, you’re left with wondering why our patients are dying when they look like they’re very healthy 20-year-olds.”
They found that correctly coding urosepsis and UTIs also saved money — an estimated cost difference of $7,000 when they conditions were appropriately coded.
For many physicians, though, the transition to ICD-10 can seem burdensome. They translate the additional or new codes as extra work and documentation. CDI specialists can serve an important role in training physicians because they can show providers how they can integrate coding into their work flows.
“As a physician, I don’t want too many things when it comes to documentation. Don’t make me lie; don’t make me do it for financial purposes. Tell me why we do it, and I will change the behavior,” said Dr Feghali. “I don’t think there’s a physician on earth who is going to say, ‘I don’t care how I look, so I’m going to keep writing it the wrong way.’”
Around the Web
CDI Produces Financial, Clinical Benefits Apart from ICD-10 [EHR Intelligence]
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
More Care Doesn't Equal Happier Patients in Traditional Medicare
March 17th 2025Data on care satisfaction, ease managing care, and out-of-pocket spending were the outcomes of interest for this new analysis that investigated the relationship between healthcare utilization and beneficiary experience within traditional Medicare.
Read More
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More